ARCHIVES

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

This article is from The Cancer Letter archive.

Vol. 32 No. 01 | January 13, 2006

Download PDF Visit The Full Archive

Related Articles

Monroe Wall, Co-Discoverer Of Taxol, Camptothecin, Dead At 85

July 12, 2002

Congress Orders Programs In Nutrition Research; Cancer Act Extension Beefs Up NCI Chief’s Authority

July 12, 1974

FEBT, For Pain Control, Shows Positive Results In Phase III

May 26, 2006

Hopkins Challenges Litton For Research Contract At FCRF

April 16, 1982

FDA’s Young Still Not Satisfied With Distribution Plan

September 9, 1977

GAO Criticizes Distribution Of Comprehensive Cancer Centers, Cite Needs for “Focal Point” Clarification

March 26, 1976